Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Lutz

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Journal of Clinical Gastroenterology|February 22, 2019
Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?Jenny Bischoff, Christoph Boesecke, Patrick Ingiliz, et al.
Neuropsychobiology|February 12, 2025
Impact of an App-Based Resilience Training on Enhancing Stress Regulation and Mental HealthMelanie Lenger, Elena M D Schönthaler, Alina Hantke, et al.
The Journal of Infectious Diseases|July 14, 2019
Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling AnalysisNatasha K Martin, Klaus Jansen, Matthias An der Heiden, et al.
Infection|October 21, 2015
Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcomeChristoph Boesecke, Patrick Ingiliz, Thomas Reiberger, et al.
Antiviral Therapy|December 4, 2014
Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfectionKarin Neukam, Daniela Munteanu, Sebastian Haubitz, et al.
Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical TrialSharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.
Bioconjugate Chemistry|September 30, 2020
Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating PeptidesAudrey Stoessel, Nadja Groysbeck, Lucile Guyot, et al.
HIV Medicine|May 30, 2024
Recently acquired HCV infection in men who have sex with men in Germany in the direct-acting antivirals era and during the COVID-19 pandemicPatrick Ingiliz, Thomas Lutz, Knud Schewe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2022
Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study)Malte B Monin, Patrick Ingiliz, Thomas Lutz, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Journal of Clinical Gastroenterology|February 22, 2019
Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?Jenny Bischoff, Christoph Boesecke, Patrick Ingiliz, et al.
Neuropsychobiology|February 12, 2025
Impact of an App-Based Resilience Training on Enhancing Stress Regulation and Mental HealthMelanie Lenger, Elena M D Schönthaler, Alina Hantke, et al.
The Journal of Infectious Diseases|July 14, 2019
Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling AnalysisNatasha K Martin, Klaus Jansen, Matthias An der Heiden, et al.
Infection|October 21, 2015
Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcomeChristoph Boesecke, Patrick Ingiliz, Thomas Reiberger, et al.
Antiviral Therapy|December 4, 2014
Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfectionKarin Neukam, Daniela Munteanu, Sebastian Haubitz, et al.
Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical TrialSharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.
Bioconjugate Chemistry|September 30, 2020
Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating PeptidesAudrey Stoessel, Nadja Groysbeck, Lucile Guyot, et al.
HIV Medicine|May 30, 2024
Recently acquired HCV infection in men who have sex with men in Germany in the direct-acting antivirals era and during the COVID-19 pandemicPatrick Ingiliz, Thomas Lutz, Knud Schewe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2022
Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study)Malte B Monin, Patrick Ingiliz, Thomas Lutz, et al.
Pageof 12